Jiangsu Hengrui Pharma 
Welcome,         Profile    Billing    Logout  
 196 Products   52 Diseases   196 Products   3529 Trials   15381 News 


«12...152153154155156157158159160161162...208209»
  • ||||||||||  hetrombopag (SHR 8735) / Jiangsu Hengrui Medicine
    Clinical, Journal:  First-in-patient study of hetrombopag in patients with chronic idiopathic thrombocytopenic purpura. (Pubmed Central) -  May 15, 2021   
    Hetrombopag was well tolerated and preliminary efficacious. Efficacy, safety and PK data suggested that 7.5 mg hetrombopag once daily was the anticipated therapeutic dose of hetrombopag in CITP patients and have been recommended to investigate in the later confirmatory clinical study of hetrombopag.
  • ||||||||||  imrecoxib (BAP 909) / Jiangsu Hengrui Medicine
    Clinical, Journal, HEOR:  Cost-utility analysis of imrecoxib compared with celecoxib for patients with osteoarthritis. (Pubmed Central) -  May 15, 2021   
    Although there were uncertainties, imrecoxib was the more cost-effective option compared to celecoxib, with a definite possibility. Due to the limitations of the original model and this study, the results of this study should be adopted with caution.
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Clinical, Review, Journal:  Apatinib-Induced Hand-Foot Skin Reaction in Chinese Patients With Liver Cancer. (Pubmed Central) -  May 14, 2021   
    In this review, we summarize and review the current efficacy of apatinib and the prevalence of AI-HFSR in Chinese patients with liver cancer. Besides, we postulate the potential mechanisms underlying the development of AI-HFSR and discuss the optimal clinical management for this unwanted cutaneous side effect.
  • ||||||||||  AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
    Trial completion, Trial completion date:  Study to Evaluate the Mass Babance and Biotransformation of [14C]SHR6390 in Healthy Adult Male Volunteers (clinicaltrials.gov) -  May 11, 2021   
    P1,  N=6, Completed, 
    The fiber device provides a platform to sequentially co-deliver dual or multiple drugs for enhanced combined therapeutic efficacy. Active, not recruiting --> Completed | Trial completion date: Dec 2021 --> May 2021
  • ||||||||||  SHR-1707 / Jiangsu Hengrui Pharma
    Enrollment open:  A Trial of SHR-1707 in Healthy Young Adult and Elderly Subjects (clinicaltrials.gov) -  May 11, 2021   
    P1,  N=62, Recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Dec 2021 --> May 2021 Not yet recruiting --> Recruiting
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Biomarker, Journal, Tumor microenvironment:  Jet-Lagged Nanoparticles Enhanced Immunotherapy Efficiency through Synergistic Reconstruction of Tumor Microenvironment and Normalized Tumor Vasculature. (Pubmed Central) -  May 11, 2021   
    Herein, Jet-lagged nanoparticles, apatinib (APA)-loaded TEC-targeting nanodrug (APA/MCP) and lonidamine (LND)-loaded tumor cell-targeting nanodrug (LND/MCA), are constructed to combine vascular normalization therapy and tumor cell metabolic treatment...Moreover, the results of in vivo pharmacodynamic studies show that after the above synergistic reconstruction of TME and normalized tumor vasculature, the therapeutic effect of programmed death 1 (PD-1) drug is improved 3-folds to that of the PD-1 group. Above all, the strategy in this paper may propose an innovative vision to facilitate the tumor immunotherapy through high-precision spatiotemporal delivery strategy of nanodrugs.
  • ||||||||||  retlirafusp alfa (SHR-1701) / Jiangsu Hengrui Pharma
    Trial completion date, Trial primary completion date:  SHR-1701-001AUS: A Trial of SHR-1701 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) -  May 10, 2021   
    P1,  N=48, Recruiting, 
    Therefore, the present findings may enhance the current knowledge of the effect of apatinib on gastric carcinoma cells. Trial completion date: Sep 2021 --> May 2022 | Trial primary completion date: Mar 2021 --> Dec 2021
  • ||||||||||  AiRuiKa (camrelizumab) / Incyte
    Clinical, Journal:  Aggravation of depigmentation for a non-small-cell lung cancer patient with pre-existing vitiligo using anti-programmed cell death-1 therapy: case report. (Pubmed Central) -  May 6, 2021   
    Some studies found that patients with autoimmune or inflammatory disease are susceptible to immune checkpoint inhibitors and were associated with a significantly increased risk of immune-related adverse events. In our present report, we described a newly diagnosed non-small-cell lung cancer patient who suffered from focal vitiligo for approximately ten years and was treated with the anti-programmed cell death-1 receptor antibody camrelizumab (SHR-1210), which accelerated the aggravation of depigmentation of the skin over the whole body in just half a year.
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
    Clinical, Retrospective data, Journal:  Apatinib combined with S-1 as second-line therapy in advanced gastric cancer. (Pubmed Central) -  May 5, 2021   
    ECOG PS was the independent factor of PFS and OS for AGC patients. AEs were moderate and controllable, and leukopenia or hypertension was predictable factors for the PFS and OS of AGC patients.
  • ||||||||||  mecapegfilgrastim (pegfilgrastim biosimilar) / Jiangsu Hengrui Medicine
    [VIRTUAL] Incidence of neutropenia in breast cancer patients with administration of mecapegfilgrastim. () -  Apr 29, 2021 - Abstract #ASCO2021ASCO_5663;    
    Prophylactic administration of mecapegfilgratim reduced the incidence of grade 3/4 neutropenia/febril neutropenia . Baseline hemoglobin level and specific chemotherapy regimen could be a useful prognostic facots for neutropenic events after administered mecapegfilgrastim.